Popular terms

[SEARCH]

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Cholesterol patents



      
           
This page is updated frequently with new Cholesterol-related patent applications. Subscribe to the Cholesterol RSS feed to automatically get the update: related Cholesterol RSS feeds. RSS updates for this page: Cholesterol RSS RSS



Date/App# patent app List of recent Cholesterol-related patents
07/30/15
20150210685 
 Novel azabenzimidazole tetrahydropyran derivatives patent thumbnailnew patent Novel azabenzimidazole tetrahydropyran derivatives
Novel compounds of the structural formula (i) are activators of amp-protein kinase and may be useful in the treatment, prevention and suppression of diseases mediated by the ampkactivated protein kinase. The compounds of the present invention may be useful in the treatment of type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension..
Merck Sharp & Dohme Corp.


07/30/15
20150209383 
 Methods and compositions for modulating gastrointestinal bacteria to promote health patent thumbnailnew patent Methods and compositions for modulating gastrointestinal bacteria to promote health
Methods and compositions for treating medical conditions or improving health in which the composition is ingested in an amount sufficient to modify the proportion of bacteria in a gut microbiome of the individual ingesting the composition. The composition may comprise polydextrose or soluble com fiber, for example.
General Mills, Inc.


07/30/15
20150209290 
 Bilayered composite tablet formulation comprising atorvastatin, irbesartan and magnesium carbonate patent thumbnailnew patent Bilayered composite tablet formulation comprising atorvastatin, irbesartan and magnesium carbonate
Disclosed are a bilayered composite tablet formation comprising (a) a first layer comprising irbesartan or a pharmaceutically acceptable salt thereof; and (b) a second layer comprising atorvastatin or a pharmaceutically acceptable salt thereof and magnesium carbonate (mgco3) in a weight ratio of 1:4 to 1:5, and a method for preparing the same. Exhibiting excellent dissolution rates and bioavailability, the bilayered composite tablet formulation is useful as a therapeutic for hypertension and hypercholesterolemia..
Hanmi Pharm. Co., Ltd


07/23/15
20150204811 
 Apparatus and  measuring cholesterol patent thumbnailApparatus and measuring cholesterol
Disclosed are an apparatus and a method for effectively measuring cholesterol using a small amount of blood. The apparatus for measuring cholesterol includes a cartridge where an upper case having a sample transferring membrane is movably coupled to a lower case having a sample measuring membrane; a cartridge accommodation unit configured to accommodate the cartridge therein; a memory configured to store therein setting information for sample measurement; and a controller configured to align the membranes of the upper case and the lower case with each other, by horizontally moving the lower case of the cartridge, according to the stored setting information, and configured to contact the membranes of the upper case and the lower case with each other, by vertically moving the upper case for sample transfer on each alignment position..
Lg Electronics Inc.


07/23/15
20150203487 
 Novel azabenzimidazole tetrahydrofuran derivatives patent thumbnailNovel azabenzimidazole tetrahydrofuran derivatives
Novel compounds of the structural formula (i) are activators of amp-protein kinase and may be useful in the treatment, prevention and suppression of diseases mediated by the ampk-activated protein kinase. The compounds of the present invention may be useful in the treatment of type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension..
Merck Sharp & Dohme Corp.


07/23/15
20150202167 
 Trans-clomiphene formulations and uses thereof patent thumbnailTrans-clomiphene formulations and uses thereof
The present invention provides iraws-clomiphene and pharmaceutically acceptable salts and solvates thereof, characterized in that trans-clomiphene is in particulate form having a specific size range. The invention is also directed to pharmaceutical compositions comprising or formulated using trans-clomiphene or pharmaceutically acceptable salts and solvates having a specified size range and their use in treating disorders including secondary hypogonadism, type 2 diabetes, elevated cholesterol, elevated triglycerides, wasting, lipodystrophy, female and male infertility, benign prostate hypertrophy, prostate cancer, breast cancer, ovarian cancer and endometrial cancer..
Repros Therapeutics Inc.


07/16/15
20150198585 
 Methods, compositions and kits for assaying mitochondrial function patent thumbnailMethods, compositions and kits for assaying mitochondrial function
The invention provides methods, compositions, devices, and kits relating to the use of cholesterol-dependent cytolysins (e.g., pfos) for measuring intracellular mitochondrial activity.. .
Baystate Medical Center, Inc.


07/16/15
20150197564 
 Anti-angptl3 antibodies and uses thereof patent thumbnailAnti-angptl3 antibodies and uses thereof
A fully human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits or interferes with at least one activity of human angiopoietin-like protein 3 (hangptl3) is provided. The human anti-hangptl3 antibodies are useful in treating diseases or disorders associated with angptl3, such as hyperlipidemia, hyperlipoproteinemia and dyslipidemia, including hypertriglyceridemia, hypercholesterolemia, chylomicronemia, and so forth.
Regeneron Pharmaceuticals, Inc.


07/16/15
20150197516 
 Novel benzimidazole tetrahydropyran derivatives patent thumbnailNovel benzimidazole tetrahydropyran derivatives
Novel compounds described herein are activators of amp-protein kinase and may be useful in the treatment, prevention and suppression of diseases mediated by the ampkactivated protein kinase. The compounds of the present invention may be useful in the treatment of type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension..
Merck Sharp & Dohme Corp. A Corporation, A Subsidiary Of Merck & Co., Inc.


07/16/15
20150196581 
 Compositions for external application, containing adenosylcobalamin for improvement of skin diseases patent thumbnailCompositions for external application, containing adenosylcobalamin for improvement of skin diseases
The present invention relates to a composition for external application for improving a skin disease (e.g. Psoriasis).
Hanall Biopharma Co., Ltd.


07/16/15
20150196571 

Process and composition for stabilization of vulnerable plaque utilizing a combination of a statin and omega 3 fatty acids


A composition and a method of treatment utilizing a combination of statins (or hmg-coa reductase inhibitors), a class of drug used to lower cholesterol levels by inhibiting the enzyme hmg-coa reductase, with mixtures of an omega-3 fatty acid formulation containing about 90% or more omega 3 fatty acids by weight including a combination of eicosapentaenoic acid (epa), docosapentaenoic acid (dpa) and docosahexaenoic acid (dha) in a weight ratio of epa:dha of from 5.7 to 6.3, wherein the sum of the epa, dha and dpa represent about 82% by weight of the total formulation and about 92% of the total omega 3 fatty acid content of the composition, the compositions and method designed to stabilize vulnerable plaque while mediating omega-3 deficiencies in individuals in need thereof.. .
Pivotal Therapeutics Inc.


07/16/15
20150196538 

Therapeutic agent for dyslipidemia


The present invention addresses the problem of providing a pharmaceutical combination composition and drug combinations for the prevention and/or treatment of dyslipidemic conditions such as atherosclerosis, hypercholesterolemia, low hdl blood disease in mammals including humans. A pharmaceutical composition for the prevention and/or treatment of dyslipidemia, etc.
Kowa Company, Ltd.


07/09/15
20150191495 

Antidiabetic tricyclic compounds


Novel compounds of the structural formula (i), and the pharmaceutically acceptable salts thereof, are agonists of g-protein coupled receptor 40 (gpr40) and may be useful in the treatment, prevention and suppression of diseases mediated by the g-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia..
Merck Sharp & Dohme Corp.


07/09/15
20150190369 

Quercetin-3-glucoside and uses thereof


There is described herein a use of quercetin-3-o-β-d-glucoside (q3g) for increasing the amount of cell surface low-density lipoprotein receptor (ldlr) on a cell and for reducing the amount of functional proprotein convertase subtilisin/kexin type 9 (pcsk9) secreted by the cell, where the q3g is formulated for administration to the cell, and where the increase in cell surface ldlr and the decrease in secretion of functional pcsk9 is in comparison to the cell not exposed to q3g. The use may optionally include the treatment of a statin.

07/09/15
20150189906 

Roast chicken preparation method


A roast chicken preparation method, and more specifically relates to a roast chicken preparation method in which an uncooked chicken is pre-seasoned by rubbing in, putting on pre-seasoning ingredients such as garlic and red pepper powder salt, then the smell of chicken meat is removed by carrying out a meat-tenderization process via low temperature refrigerated maturation, then a batter coating is put on with a batter flour obtained by mixing wheat flour and corn starch with salt, pepper, garlic powder, whole peppers, ginger powder, chili powder or the like and frying is carried out in a mixed oil, and then the oil is taken off and roasting is carried out using a grill briquette direct flame fire, such that the roast chicken is one wherein greasiness has been removed by subjecting a chicken from a fried chicken step to a briquette direct flame roasting step; and the invention is useful in that greasiness is removed and clings less than with common fried chickens, the risk of taking in large volumes of cholesterol is overcome, storage properties after preparation are improved, and a crispy flavour is achieved even though the inside is moist and soft as the water fraction in the meat juices is conserved.. .

07/02/15
20150182600 

Methods of treating anemia and red blood cell dysfunction with lecithin cholesterol acyltransferase


Disclosed are methods for treating conditions characterized by anemia or red blood cells dysfunction by administering an agent that increases the level of endogenous lcat or lcat activity. Additionally disclosed are methods of treating conditions wherein red blood cells have reduced function in relation to deformability, oxygenation, increased adhesion and aggregability, reduced nitric oxide function, or decreased life-span, increased free cholesterol, or abnormal phospholipid content.
Alphacore Pharma, Llc


07/02/15
20150182597 

Compositions comprising hyaluronic acid and dermatan sulphate for the treatment of being overweight and obesity


The present invention relates to a composition comprising hyaluronic acid and dermatan sulphate for use in the treatment or prevention of overweight, obesity, insulin resistance, type 2 diabetes, fatty liver or dyslipidemia or for use in reducing food intake, inducing the feeling of satiety, reducing appetite, reducing body weight, preventing weight gain, reducing body fat, reducing fat formation, reducing blood cholesterol, maintaining normal blood cholesterol levels, reducing blood triglycerides, maintaining normal blood triglyceride levels or increasing insulin sensitivity. The composition can further contain collagen hydrolysate.
Bioiberica, S.a.


07/02/15
20150182593 

Composition for treating hyperlipidemia comprising oxyntomodulin derivative


The present invention relates to a composition for preventing or treating hyperlipidemia, fatty liver disease or arteriosclerosis, comprising an oxyntomodulin derivative as an active ingredient. The oxyntomodulin derivative has a high ability to activate glp-1 receptor and glucagon receptor compared to native oxyntomodulin and has the effects of reducing the blood total cholesterol, low-density cholesterol and triglyceride levels that were increased by high-fat diet, and increasing high-density cholesterol levels and the high-density cholesterol/low-density cholesterol ratio.
Hanmi Pharm. Co., Ltd.


07/02/15
20150182590 

Vesicles comprising epidermal growth factor and compositions thereof


The invention relates to vesicles comprising epidermal growth factor (egf), a cationic surfactant and cholesterol or derivatives thereof. The invention also discloses a procedure for their preparation, based on compressed fluid technology (cfs).
Consejo Superior De Investigaciones Cientificas


07/02/15
20150182515 

Methods for treating obesity and disorders associated with hyperlipidemia in a mammal


The disclosure relates to methods for treating hyperlipidemia in a mammal. The present disclosure also relates to methods for treating and/or controlling obesity in a mammal.
Aegerion Pharmaceuticals, Inc.


06/25/15
20150176050 

Dry chemistry, lateral flow-reconstituted chromatographic enzyme-driven assays


Specific assays for glucose-6-phosphate dehydrogenase (“g-6pd”), total serum cholesterol, β-lactamase activity and peroxidase activity are disclosed.. .

06/25/15
20150175956 

Media for cell culture


The present disclosure relates, in general, to a media, e.g., a serum replacement, media supplement, complete media or cryopreservation media, comprising a base physiological buffer and liposomes comprising cholesterol, phosphatidylcholine and fatty acids. It is contemplated that media provides advantages to improve cell growth in culture compared to cells cultured not using the serum replacement described herein..
Essential Pharmaceuticals, Llc


06/25/15
20150174152 

Fat binder obtained from biomass resulting from beer production


The present invention provides a polysaccharide rich composition comprising beta-glucan, chitin and chitosan, extracted from the cell wall of saccharomyces cerevisiae from the by-product biomass resulting from a brewing process, the process for obtaining it and the uses thereof. The composition exerts, among other biofunctionalities, a selective fat binding effect so it is useful in the prevention and/or treatment of a disorder such as overweight, obesity, hypercholesterolemia, hypertriglyceridemia, blood hypertension and cardiovascular disorders.
S.a. Damm


06/25/15
20150174069 

Methods of treating arthritis


Disclosed herein are methods of treating arthritis, comprising administering a sustained release composition comprising liposomes comprising one or more phospholipids, cholesterol, and a therapeutic agent. The sustained release composition can be administered intraarticularly..
Tlc Biopharmaceuticals, Inc.


06/25/15
20150173389 

Method for producing high quality animal oil with low cholesterol levels


The invention provides a method for producing high-quality lard or beef tallow with low cholesterol content. The method of the invention uses enzyme hydrolysis, centrifugation separation and homogenization-assisted embedding technique to obtain high-quality lard or beef tallow with low cholesterol levels.
Jiangnan University


06/18/15
20150167005 

Methods for treating hypercholesterolemia


Disclosed herein are antisense compounds and methods for decreasing ldl-c in an individual having elevated ldl-c. Additionally disclosed are antisense compounds and methods for treating, preventing, or ameliorating hypercholesterolemia and/or atherosclerosis.
Isis Pharmaceuticals, Inc.


06/18/15
20150166975 

Cell and enzyme compositions for modulating bile acids, cholesterol and triglycerides


C) a carrier.. .

06/18/15
20150166672 

Precision medicine by targeting rare human pcsk9 variants for cholesterol treatment


The invention relates to human targets of interest (toi), anti-toi ligands, kits compositions and method.. .
Kymab Limited


06/18/15
20150166566 

Thienopyridone derivatives useful as activators of ampk


Activators of ampk and therapeutic uses thereof the invention relates to compounds that are direct activators of ampk (amp-activated protein kinase) and their use in the treatment of disorders regulated by activation of ampk. For instance, compounds according to the invention are useful for the treatment of diabetes, metabolic syndrome, obesity, liver disease, hepatic steatosis, non alcoholic fatty liver disease (nafld), non alcoholic steato-hepatitis (nash), liver fibrosis, dyslipidemia, hypertriglyceridemia, hypercholesterolemia, inflammation, cancer, cardiovascular diseases, atherosclerosis, high blood pressure, retinopathies or neuropathies..
Poxel


06/18/15
20150164969 

Anti-obesity and anti-dyslipidemic effects of oil palm phenolics in treating atherosclerosis and cardiovascular disease


A composition comprising extracts containing oil palm phenolics in an amount effective for use in a method of reducing cholesterol biosynthesis and thus preventing obesity. The composition up regulates fatty acid beta oxidation and down regulates cholesterol biosynthesis in livers.
Malaysian Palm Oil Board


06/18/15
20150164893 

Pharmaceutical formulations for carrier-mediated transport statins and uses thereof


The present invention relates to formulations comprising therapeutically effective amounts of at least one acid-stable, carrier-mediated transport statin, at least one poorly water-soluble, carrier-mediated transport statin, or at least one large molecular weight, carrier-mediated transport statin, such as atorvastatin and rosuvastatin, or a pharmaceutically acceptable salt thereof, and methods of their use. The present formulations and methods are designed to exhibit a controlled-release of a therapeutic amount of the statin in the small intestine, thereby limiting systemic exposure of the statin and maximizing liver-specific absorption of the drug.
Circ Pharma Research And Development Limited


06/18/15
20150164787 

Process for forming microbubbles with high oxygen content and uses thereof


Formulations containing a carrier and microbubbles encapsulating oxygen gas, and methods for making and using the formulations are described herein. The formulations are manufactured by a process which includes high shear homogenization.
Children's Medical Center Corporation


06/11/15
20150159115 

Purification of dpa enriched oil


The present invention provides chromatographic means for separating from a starting lipid mixture a mixture that is enriched in docosapentaenoic acid relative to the starting lipid mixture. The invention also provides pharmaceutical formulations and dietary supplements including this enriched lipid formulation, and methods of supplementing docosapentaenoic acid in a subject by administering to the subject the pharmaceutical formulation or the dietary supplement.
Omega Protein Corporation


06/11/15
20150157572 

Proliposomal testosterone formulations


Novel testosterone formulations are disclosed where testosterone is incorporated into a phospholipid/cholesterol system to produce a proliposomal powder dispersion. The proliposomal powder dispersions of the invention may be formulated with phamarceutically acceptable excipients to form pharmaceutical compositions.
Tesorx Pharma, Llc


06/11/15
20150157570 

Tailored liposomes for the treatment of bacterial infections


The invention relates to the use of empty liposomes of defined lipid composition or mixtures of empty liposomes of defined lipid composition and to the use of other lipid bilayers or monolayers of defined lipid composition for the treatment and prevention of bacterial infections. It has been found that such liposomes, in particular a two- and a four-component mixture of liposomes comprising cholesterol and sphingomyelin, liposomes consisting of sphingomyelin, liposomes comprising sphingomyelin and phosphatidylcholine, and liposomes comprising cholesterol and phosphatidylcholine efficiently sequestrate a variety of toxins secreted by bacteria, thus preventing binding of bacterial toxins to target cells and toxin-induced lysis of the target cells.
Universitaet Bern


06/04/15
20150153342 

Serological methods and diagnostic tests for syphilis antibodies


A method of detecting antibodies to syphilis antigens includes providing a syphilis detection kit having a screening solid-phase platform with a screening portion coated with non-treponemal syphilis antigens. The screening portion is fabricated by initially dissolving cholesterol in an organic solvent and further diluting the dissolved cholesterol in an ethanol solution comprising cardiolipin and lecithin to form an antigen solution, permitting the antigen solution to evaporate at the screening portion and at least partially coating the screening portion with an antigen coating, and stabilizing the antigen coating into a syphilis antigen complex by overcoating the antigen coating with an overcoat solution comprising an inert protein..
Awareness Technology Inc.


06/04/15
20150152102 

Piperidinylpyrazolopyridine derivative


A compound represented by the general formula (i) or a pharmacologically acceptable salt thereof has an excellent lcat-activating effect and is useful as an active ingredient in a therapeutic or prophylactic agent for arteriosclerosis, arteriosclerotic heart disease, coronary heart disease (including heart failure, myocardial infarction, angina pectoris, cardiac ischemia, cardiovascular disturbance, and restenosis caused by angiogenesis), cerebrovascular disease (including stroke and cerebral infarction), peripheral vascular disease (including diabetic vascular complications), dyslipidemia, hypo-hdl-cholesterolemia, or renal disease, particularly, an anti-arteriosclerotic agent, wherein r is an optionally substituted aryl group or an optionally substituted heteroaryl group.. .
Daiichi Sankyo Company, Limited


05/28/15
20150148360 

3,5,n-trihydroxy-alkanamide and derivatives: making same and use thereof


The present invention provides novel compounds of formula (i), and pharmaceutically compositions thereof. Compounds of formula (i) are inhibitors of histone deacetylases (hdacs) and 3-hydroxy-3-methylglutaryl coenzyme a (hmg-coa) reductase (hmgr).
National Taiwan University


05/28/15
20150147320 

Ophthalmic drug delivery system containing phospholipid and cholesterol


An ophthalmic drug delivery system that contains phospholipid and cholesterol for prolonging drug lifetime in the eyes.. .
Tlc Biopharmaceuticals, Inc.


05/28/15
20150146205 

Measurement of serum lipoproteins


Although a more accurate estimate of a person's risk of cardiovascular disease can be made on the basis of the number of lipoprotein particles per unit volume in the person's blood, current methods all rely on measuring the mass of lipoprotein cholesterol per unit volume. It has been discovered that a rapid and accurate lipoprotein particle count can be obtained by photometry.
Atherotech,inc.


05/21/15
20150141371 

Method of using nutritional compounds dihydroquercetin (taxifolin) and arabinogalactan in combination with dihydroquercetin (taxifolin) to reduce and control cardiometabolic risk factors associated with metabolic syndrome and hypercholesterolemia


A composition for use in a human by oral administration to reduce or control cardiometabolic risk factors associated with metabolic syndrome or hypercholesterolemia, or reduce risk of developing metabolic syndrome or hypercholesterolemia. The composition includes a combination of arabinogalactan and dihydroquercetin (taxifolin), where the arabinogalactan is present in the combination as a fiber matrix in an amount higher than 70% as determined by weight on dry matter basis, and the dihydroquercetin is present in the fiber matrix..
Flavitpure, Inc.


05/21/15
20150141355 

Salacia compositions, methods of treatment by their administration, and methods of their preparation


A salacia composition described herein significantly reduces appetite, activates hormone sensitive lipase, and manages a healthy lipid profile through inhibition of hmg-coa reductase enzyme. Salacia compositions described herein include of at least 12% of polyphenols, 2% of mangiferin and 1% of 25,26-oxidofriedelane-1,3-dione by weight of the composition in the form of extract.
Omniactive Health Technologies (canada) Limited


05/21/15
20150140650 

Systems and methods for cryopreservation of cells


An auto-nucleating device includes a tube containing a crystalline cholesterol matrix. The ends of the tube are closed by a membrane that is impermeable to the cholesterol but permeable to liquids contained in a cryopreservation vessel.
Cook General Biotechnology Llc


05/21/15
20150140142 

Medicinal composition of extract of seed of emblica officinalis and preparing the same


A composition having an extract of seed of emblica officinalis. Methods of preparing extract of seed of emblica officinalis.

05/21/15
20150140004 

Hydroxycholesterol immunoassay


Provided is a derivative of 22-hydroxycholesterol, 24s-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol. Also provided is a protein conjugated to the above derivative.
Enzo Life Sciences, Inc. C/o Enzo Biochem, Inc.


05/21/15
20150139987 

Treatment of homozygous familial hypercholesterolemia


Treatment of homozygous familial hypercholesterolemia by administration of (r)-2-(4-((2-ethoxy-3-(4-(trifluoromethyl)phenoxy)propyl)thio)-2-methylphenoxy)acetic acid or a salt thereof, optionally in combination with an mtp inhibitor, an apob-100 synthesis inhibitor, or a pcsk9 inhibitor.. .
Cymabay Therapeutics, Inc.


05/14/15
20150133554 

Purification of dpa enriched oil


The present invention provides chromatographic means for separating from a starting lipid mixture a mixture that is enriched in docosapentaenoic acid relative to the starting lipid mixture. The invention also provides pharmaceutical formulations and dietary supplements including this enriched lipid formulation, and methods of supplementing docosapentaenoic acid in a subject by administering to the subject the pharmaceutical formulation or the dietary supplement.

05/14/15
20150133519 

Novel diester and triester based low molecular weight, biodegradeable cationic lipids for oligonucleotide delivery


The instant invention provides for novel cationic lipids of formula a that can be used in combination with other lipid components such as cholesterol and peg-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that demonstrates enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver.

05/14/15
20150133508 

Use of quaternary pyridinium salts as vasoprotective agents


Wherein r is nh2, ch3, or n(h)ch2oh group, and x is pharmaceutically acceptable counterion, for the preparation of vasoprotective agent for the treatment or prevention of conditions or diseases associated with dysfunction of vascular endothelium, oxidative stress, and/or insufficient production of endothelial prostacyclin pgi2, in particular but not exclusively if the above coincides with hypercholesterolemia, hypertriglyceridemia or low hdl level.. .

05/14/15
20150133420 

Broad antiviral therapy with membrane modifying oxysterols


This invention relates, e.g., to a method for inhibiting the growth and/or proliferation and/or infectivity of a virus in a cell, such as a mammalian cell (e.g. For inhibiting entry of the virus into the cell), comprising administering, or causing to be administered, to the cell, 25-hydroxycholesterol (25hc) in an amount sufficient to inhibit the growth and/or proliferation and/or infectivity of the virus in the cell.

05/14/15
20150132834 

Method for removal of triglycerides in lipoproteins other than low-density lipoproteins


Disclosed is a method for selectively eliminating triglycerides in lipoproteins other than low density lipoprotein, which method allows one to provide a method for directly and differentially quantifying ldl-tg in a sample with excellent simplicity, specificity and accuracy using an automated analyzer or the like without performing a laborious operation of pretreatment such as centrifugation or electrophoresis. The method for eliminating triglycerides in lipoproteins other than low density lipoproteins includes allowing lipoprotein lipase, cholesterol esterase, glycerol kinase and glycerol-3-phosphate oxidase to act on a sample in the presence of a surfactant that acts on lipoproteins other than low density lipoprotein and/or a surfactant having ldl-protecting action, and eliminating hydrogen peroxide produced thereby..

05/14/15
20150132431 

Cholesterol-reducing diet


A method of treating macular degeneration comprising a specific dietary regimen. The regimen includes lipids as approximately 70% or more of daily caloric content, protein up to 10%-15% of daily caloric content; and carbohydrates up to 25% or less of daily caloric content, primarily in the form of non-starchy, low-glycemic fresh fruit and vegetables, and nuts, average daily cholesterol intake of less than 10 mg, and 30 grams of cocoa solids..

05/07/15
20150125568 

Healthy composition for lowering cholesterol for use in foods, beverages, health supplements and medical foods


Disclosed is a composition consisting of beta-glucan (1,3), (1,4) β-d glucan), plant sterols and a hydrocolloid. A natural way to help lower blood serum cholesterol levels to a consumer and or patient with the effective amount of disclosed composition.

04/30/15
20150119458 

4-((substituted phenyl) difluoromethyl) phenoxy carboxylic acid derivative, and preparation method and uses thereof


The present invention discloses a 4-((substituted phenyl)difluoromethyl)phenoxycarboxylic acid derivative and preparation process and use thereof. More specifically, the present invention relates to a compound of the following formula i, which is defined in the specification.
Zhejiang Hisun Pharmaceutical Co., Ltd.


04/30/15
20150119414 

Statin and omega 3 fatty acids for reduction of apolipoprotein-b levels


A composition and a method of treatment utilizing a combination of statins (or hmg-coa reductase inhibitors), a class of drug used to lower cholesterol levels by inhibiting the enzyme hmg-coa reductase, with mixtures of an omega-3 fatty acid formulation containing about 90% or more omega 3 fatty acids by weight including a combination of eicosapentaenoic acid (epa), docosapentaenoic acid (dpa) and docosahexaenoic acid (dha) in a weight ratio of epa:dha of from 5.7 to 6.3, wherein the sum of the epa, dha and dpa represent about 82% by weight of the total formulation and about 92% of the total omega 3 fatty acid content of the composition are taught.. .
Pivotal Therapeutics Inc.


04/30/15
20150119406 

Tricyclic pyrone compounds reduce amyloid beta aggregates


Tricyclic pyrone compounds having high oral bioavailability, excellent blood-brain barrier permeability, and low toxicity are presented. Administration of the compounds to alzheimer's disease transgenic models resulted in substantially reduced soluble and insoluble aβ species in the brain without affecting general behavior and motor coordination.
The Regents Of The University Of California


04/30/15
20150119388 

Novel pro- and codrug derivatives for nanoparticle delivery of select anticancer agents formed using rapidly cleavable phenolic ester bridges


An ester of aroh according to the formula r—x—co—oar, wherein aroh is a pharmaceutically active compound selected from the group consisting of sn-38, pi-103, etoposide and fenretinide, wherein a) r is a residue of cholesterol, sitosterol, sn-38, pi-103, etoposide or fenretinide and x is o—co-l, wherein l is either a direct bond or a linking group including a branched or unbranched hydrocarbyl moiety that may optionally include in-chain or pendant heteroatom substituents and/or cyclic moieties; b) r—x—co-0 is an all-trans retinoate radical or the 9-cis or 13-cis isomer thereof; or c) r—x— is a branched or unbranched, saturated or unsaturated hydrocarbyl moiety comprising at least 5 carbon atoms and optionally including at least one in-chain or pendant heteroatom substituent and/or cyclic moiety. A dispersion of nanoparticles in an aqueous medium includes nanoparticles including an ester of aroh according to the formula r—x—co—oar wherein aroh is a pharmaceutically active compound in which ar is a substituted or unsubstituted aryl or heteroaryl radical, and wherein r is as defined above or r—x—co-0 is as defined above.
The Children's Hospital Philadelphia


04/30/15
20150119368 

Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events


A composition and a method of treatment for the reduction of risk factors for cardiovascular disease utilizing a combination of lipid lowering cholesterol absorption inhibitors, e.g. Azetidinones, with mixtures of an omega-3 fatty acid formulation containing about 90% or more omega 3 fatty acids by weight including a combination of eicosapentaenoic acid (epa), docosapentaenoic acid (dpa) and docosahexaenoic acid (dha) in a weight ratio of epa:dha of from 5.7 to 6.3, wherein the sum of the epa, dha and dpa represent about 82% by weight of the total formulation and about 92% of the total omega 3 fatty acid content of the composition are taught..
Pivotal Therapeutics Inc.


04/23/15
20150111948 

Rna-interference-inducing nucleic acid molecule able to penetrate into cells, and use therefor


The present invention relates to a novel, rnai-inducing nucleic acid molecule having cell penetrating ability and the use thereof, and more particularly, to a novel, rnai-inducing double-stranded nucleic acid molecule, which has a replacement of the phosphate backbone of at least one nucleotide with phosphorothioate or phosphorodithioate, and has a lipophilic compound conjugated thereto, and thus has high target gene-silencing efficiency while having the ability to penetrate cells without needing a separate intracellular delivery vehicle, and to a method of silencing a target gene using the nucleic acid molecule. The nucleic acid structure according to the present invention has both cholesterol modification and phosphorothioate modification introduced therein, and thus has high gene silencing efficiency while having the ability to penetrate cells without needing a separate intracellular delivery vehicle.
Bmt, Inc.


04/23/15
20150111866 

Cyclic amine substituted heterocyclic cetp inhibitors


Compounds having the structure of formula i, including pharmaceutically acceptable salts of the compounds, are cetp inhibitors and may be useful for raising hdl-cholesterol and reducing ldl-cholesterol in human patients and for treating or preventing atherosclerosis.. .
Merck Sharp & Dohme Corp.


04/23/15
20150110859 

Mrna therapy for argininosuccinate synthetase deficiency


The present invention provides, among other things, methods of treating argininosuccinate synthetase deficiency (asd), including administering to a subject in need of treatment a composition comprising an mrna encoding argininosuccinate synthetase (ass1) at an effective dose and an administration interval such that at least one symptom or feature of asd is reduced in intensity, severity, or frequency or has delayed in onset. In some embodiments, the mrna is encapsulated in a liposome comprising one or more cationic lipids, one or more non-cationic lipids, one or more cholesterol-based lipids and one or more peg-modified lipids.
Shire Human Genetic Therapies, Inc.


04/23/15
20150110858 

Mrna therapy for phenylketonuria


The present invention provides, among other things, methods of treating phenylketonuria (pku), including administering to a subject in need of treatment a composition comprising an mrna encoding phenylalanine hydroxylase (pah) at an effective dose and an administration interval such that at least one symptom or feature of pku is reduced in intensity, severity, or frequency or has delayed in onset. In some embodiments, the mrna is encapsulated in a liposome comprising one or more cationic lipids, one or more non-cationic lipids, one or more cholesterol-based lipids and one or more peg-modified lipids.
Shire Human Genetic Therapies, Inc.


04/16/15
20150104847 

Method for stabilizing cholesterol oxidase


The present invention provides a method for stabilizing a cholesterol oxidase, a method for preserving a cholesterol oxidase, and a stabilized composition of cholesterol oxidase. A method for stabilizing a cholesterol oxidase and a method for preserving a cholesterol oxidase which comprises allowing the cholesterol oxidase to coexist with an α-keto acid in an aqueous medium, and, a stabilized composition of cholesterol oxidase which comprises the cholesterol oxidase being allowed to coexist with an α-keto acid in an aqueous medium.
Kyowa Medex Co., Ltd.


04/16/15
20150104817 

Hydroxycholesterol immunoassay


Provided is a derivative of 22-hydroxycholesterol, 24s-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol. Also provided is a protein conjugated to the above derivative.
Enzo Life Sciences, Inc. C/o Enzo Biochem, Inc.


04/16/15
20150104532 

Composition to enhance hdl cholesterol and to decrease intima-media thickening in animals and humans and a its preparation


A method of producing a product to correct hypercholesterolemia including pulping fruits of emblica officinalis with demineralized water to create a slurry. The slurry is treated with pectinase.
Arjuna Natural Extracts, Ltd.


04/09/15
20150099787 

Non-flushing niacin analogues, and methods of use thereof


One aspect of the present invention relates to substituted pyridines and pharmaceutially acceptable salts thereof that are active against a range of mammalian maladies. Another aspect of the invention relates to a pharmaceutical composition, comprising a compound of the present invention or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable excipient.
Trustees Of Tufts College


04/09/15
20150099021 

Medicinal composition of extract of seed of emblica officinalis and preparing the same


A composition having an extract of seed of emblica officinalis. Methods of preparing extract of seed of emblica officinalis.

04/02/15
20150093781 

Microorganism for expressing a human membrane protein


The invention relates to an isolated, genetically modified, living non-mammal organism, having increased hmg-coa-reductase activity compared to the wild type, and having reduced c24-methyltransferase and/or delta22-desaturase activity compared to the wild type. The invention is characterized in that the organism has increased dehydrocholesterol-delta70-reductase activity compared to the wild type.
Organobalance Gmbh


04/02/15
20150093459 

Bioactive complex compositions and methods of use thereof


A bioactive complex composition having enhanced oxidative stability, emulsion stability, mineral rich transparent beverages and a wide range of functional health benefits. The composition may include as a base composition individual ingredients or a synergistic blend of mineral salts, omega-3 rich oils, phospholipids, chitosan, and alpha-casein, beta-casein, kappa-casein or protein fragments, glycopeptides, phosphopeptides.
Texas A&m University System


03/26/15
20150087819 

Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9)


Antigen binding proteins that interact with proprotein convertase subtilisin kexin type 9 (pcsk9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to pcsk9 are described.
Amgen Inc.


03/26/15
20150087649 

Treating disorders associated with aberrant adrenocortical cell behavior


Methods and agents are provided for treatment of disorders associated with aberrant adrenocortical cell behavior, including (but not limited to) treatment of adrenocortical carcinoma (acc) and/or cushing's syndrome. Such methods involve administration of an agent which exhibits an ic50 value against huacat1 of less than 10 μm, and one or more further characteristics including effects on adrenocortical cells, disruption of cholesterol homeostasis, reduction in steroid biosynthesis, reduction of mitochondrial function, and/or preferential binding to by low-density lipoprotein (ldl)..
Atterocor, Inc.


03/19/15
20150080477 

Methods and compositions for treating arteriosclerotic vascular diseases


The present invention provides methods and compositions for treating arteriosclerotic vascular diseases by cyclohexenone compounds. In some embodiments, the compound in the methods inhibits pdgf-stimulated smooth muscle cell proliferation or migration.
Golden Biotechnology Corporation


03/19/15
20150080471 

Methods for reducing triglyceride, total cholesterol and low density lipoprotein blood levels


Or a metabolite thereof, or an ester of the compound of formula (i) or the metabolite thereof, or a pharmaceutically acceptable salt of each thereof, wherein m, n, x1 and x2 are as defined herein, is useful for reducing blood levels of one or more of triglycerides (tg), total cholesterol (tc) and low density lipoprotein (ldl) in human subjects.. .

03/19/15
20150080345 

Compositions and methods for the treatment of metabolic syndrome


The invention relates to the compounds of formula i and formula ii or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula i or formula ii, and methods for treating or preventing or modulating metabolic syndrome may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection.



Popular terms: [SEARCH]



Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Cholesterol for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Cholesterol with additional patents listed. Browse our RSS directory or Search for other possible listings.


1.0034

5047

459571 - 0 - 101